Expression level of miR-383-5p in colorectal cancer patients following neoadjuvant chemotherapy and its clinical significance in the prognosis

Colorectal Cancer

Minerva Med. 2020 Jul 22. doi: 10.23736/S0026-4806.20.06656-2. Online ahead of print.


BACKGROUND: This study aims to detect expression level of microRNA-383-5p (miR-383-5p) in colorectal cancer (CRC) patients following chemotherapy and its potential influence on the prognosis in CRC.

METHODS: A total of 150 CRC patients treated in The First Affiliated Hospital of Heilongjiang University of Chinese Medicine from June 2016 to July 2019 were included. All patients were preoperatively treated by neoadjuvant chemotherapy. Serum levels of miR-383-5p in CRC patients before and after neoadjuvant chemotherapy were detected by reverse transcriptase-polymerase chain reaction (RTPCR). Univariable and multivariate unconditioned Cox hazard analyses were conducted to assess risk factors for prognosis in CRC patients. The prognostic value of miR-383-5p in CRC was examined by depicting Kaplan-Meier curves.

RESULTS: Overexpression of miR-383-5p could enhance the sensitivity of neoadjuvant chemotherapy in CRC patients. Its level was closely related to differentiation, TNM staging, lymphatic metastasis and vascular infiltration in CRC. Cox hazard analyses demonstrated that stage III+IV, lymphatic metastasis, vascular invasion and low serum level of miR-383-5p were risk factors for prognosis in CRC patients. High level of miR-383-5p was favorable to the overall survival in CRC.

CONCLUSIONS: MiR-383-5p is lowly expressed in serum of CRC patients. Upregulation of miR-383-5p is beneficial to the therapeutic efficacy of neoadjuvant chemotherapy and the prognosis in CRC.